Healthcare
Vanda Pharmaceuticals Inc.(VNDA)
Live Price
Offline$5.80
-2.68% today
1Y Change
+31.32%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $450.00M
- Revenue Growth
- +8.7%
- EPS Growth
- -1068.8%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vanda Pharmaceuticals Inc. (VNDA) is a Healthcare stock with a market cap of $450.00M and listed on NASDAQ. The stock last traded around $5.80 and up 31.3% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +8.7%, EPS growth of -1068.8%, a dividend yield of 0.0%. What stands out right now is revenue +8.7%, EPS -1068.8%, free cash flow -579.8% with operating margin -71.6% and ROIC -44.3%. Valuation is more restrained than many high-expectation growth names at price/sales 2.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VNDA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+8.7% vs +7.6% peer median
Operating Margin
Below sector median
-71.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +8.7% and EPS is at -1068.8%, with operating margin around -71.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -16.5% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | -14.1% | -13.6% | -16.0% |
2026 Feb 11, 2026 | +78.9% | -17.6% | -17.9% | +25.0% |
2025 Oct 29, 2025 | -22.6% | -20.1% | -17.9% | -2.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VNDA
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VNDA Max Drawdown
-38.60%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VNDA and SPY.
Company Overview
Vanda Pharmaceuticals Inc.
NASDAQ Global Market
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
- Leadership
- Mihael H. Polymeropoulos
- IPO Date
- Apr 12, 2006
- Employees
- 368
- Street Address
- 2200 Pennsylvania Avenue NW
- Mailing
- Washington, DC, 20037
- Region
- Washington, DC, US
- Reporting Currency
- USD
- Investor Line
- 202 734 3400
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 2.1
- Price/Book
- 1.4
Growth
- Revenue
- +8.7%
- EPS
- -1068.8%
- Free Cash Flow
- -579.8%
Profitability
- Gross Margin
- 93.2%
- Operating Margin
- -71.6%
- Net Margin
- -102.0%
- ROE
- -49.2%
- ROIC
- -44.3%
Balance Sheet
- Debt/Equity
- 0.04
- Current Ratio
- 2.39
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.